3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
10
Lung Neoplasms
9
Colorectal Neoplasms
7
Breast Neoplasms
7
Prostatic Neoplasms
6
Rectal Neoplasms
3
Polycystic Ovary Syndrome
3
Neoplasm Metastasis
3
Colonic Neoplasms
3
Stomach Neoplasms
2
Smoking Cessation
2
Neoplastic Cells, Circulating
2
Motor Activity
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
2
Endometrial Neoplasms
2
Disease
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Venous Thromboembolism
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
1
Testicular Germ Cell Tumor
1
Stroke
1
Solitary Pulmonary Nodule
1
Skin Neoplasms
1
Sezary Syndrome
1
Interventions
Ipilimumab
17
Nivolumab
15
incomplete Freund's adjuvant
8
Cyclophosphamide
7
CTLA-4 Antigen
7
pembrolizumab
6
Ranibizumab
6
sargramostim
5
Radiosurgery
5
Blood Specimen Collection
5
tebentafusp
4
Temozolomide
4
Surveys and Questionnaires
4
Magnetic Resonance Spectroscopy
4
MART-1 Antigen
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Biopsy
4
Bevacizumab
4
fludarabine phosphate
3
fludarabine
3
aflibercept
3
Thalidomide
3
Sunitinib
3
Specimen Handling
3
MAGEA3 protein, human
3
Interleukin-2
3
130-nm albumin-bound paclitaxel
3
relatlimab
2
olaparib
2
montanide ISA 51
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Uveal Melanoma
×
Hematologic Tests
×
Clear all
NCT04424719
2025-09-03
SALOME
Institut Curie
Phase NA
Recruiting
700 enrolled